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One important aspect of photome dicine is the use of 
nonionizing e lectromagnetic radiation with and without 
exogenous photosensitizers to treat diseases. Phototox-
icity (cell injury by photons) is a likely mechanism for 
phototherapy and photo chemotherapy of several skin 
diseases. The mechanism of action for phototherapy of 
hyperbilirubinemia and of uremic pruritus appears to b e 
photochemical alteration of extracellular m etabolites. 
Psorias is is an example of a disease ben efitted by several 
forms of phototherapy and photoch e mothe rapy with 
varying relative effectiveness and safe ty. Two successful 
forms of treatment are ora l psora le n photochemother-
apy and UVB plus topical adjunctive agents. New infor-
JDation about UVB therapy of p soriasis includes data 
about the therapeutic action spectrum and a bout the 
relative roles of various topical agents such a s coal tar, 
mineral oil, "lubricants" and steroids. Although there 
are many surface similarities, phototherapy and psora-
len photochemotherapy have fundamental differences 
w hich may alter longterm risks in quantitative and qual-
itative ways. 
One specific aspect of photomedicine is the use of nonionizing 
radiation in the ultraviolet and visible ra nge with and without 
t h e addi tion of exogenous photosensitizel's to treat disease. In 
most instances therapeutic mechanisms a re not known but in 
vivo photochemical studies, assumptions about the pathophys-
iology of the disease processes, and knowledge of the nature of 
the interaction of electromagnetic radiation with biologic mat· 
ter make it possible to list potential mechanisms (see T able I). 
Phototoxicity is a likely mechanism for several forms of pho-
toth erapy a nd photochemotherapy. The term phototoxicity is 
used here to describe cell injury or harmful tissue alterations 
induced by nonionizing electromagnetic radiation, especially in 
the ultraviolet and visible range. The te rm has also been used 
to refer to cell damage by photons plus photoactive chemicals. 
In the context of describing in vivo use of chemical photosen-
sitizers, the term is often used to separate nonimmunologic 
photobiologic (phototoxic) responses from those effects involv-
ing immune mecha njsms (photoallergic). The term is some-
times used by clinicians to describe the gross morphologic 
changes and by pathologists to describe a complex of histologic 
changes induced by ultraviolet radiation with or without pho-
tosensitizers regardless of molecular or cellular mechanisms. 
We suggest clearly defining phototoxicity before using it, avoid-
ing using the term, or using it, as we will in this report, in a 
general way to mean injmy or toxicity by photons. 
Ultraviolet-induced photochemist.ry within cells can lead to 
a host of chemical, metabolic, and structm al changes in bot h 
normal and abnormal cells. If enough cell injury occms in skin, 
an intlammatory reaction follows. After a latent period of 
several hours, redness, swelling, and tenderness aJ'e present in 
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exposed sites. The delayed erythema component has received 
t he most attent ion because it is easily observed by noninvasive 
techniques. U ltraviolet-induced delayed erythema is, however, 
difficult to quantify a nd its absence cannot be interpreted as 
absence of cell injury. Epiderma l cell death [1] , DNA damage 
[2] , and melanogenesis [3] can be seen after suberythemogenic 
exposures to ultraviolet radiation . Also, recent studies have 
shown that suberythemogenic exposure doses of UV alter the 
skin for at least 24 hI' so that the t hreshold for delayed erythema 
by subsequent exposures is lowered [4]. 
With qualitative and quantitative differences, the variety of 
r ad iation-induced cellular al terations and cascade of t issue re-
actions known to occur in normal skin most likely a lso occur in 
diseased skin. These differences may lead to improvement of 
diseased skin without ineversible or unacceptable da mage to 
norma l skin . For example ul traviolet radiation may decrease 
abnormal hyperproliferation or may interfere with function or 
viabili ty of abnormal cells intricately involved in pathophysio-
logical expression of disease. In ome cases abnormal cells may 
be more sensiti ve to radiation than are normal cells. Skin is a 
complex organ system which is highly overperfused and, t here-
fore, several perspectives must be considered simul taneously: 
the effect of photons on specific biomolecules, the effect on cell 
function a nd viability, and the subsequent inflammatory re-
sponse. There is repair of macromolecules such as DNA and 
repair of the organ as a whole. Ther e are many chromophores, 
photobiologic responses with separate action spectra and com-
plex interactions between these responses. 
Ultraviolet phototherapy, heliotherapy, and photochemoth-
erapy have been used for a variety of skin diseases. In many 
dermatoses effectiveness of phototherapy is difficult to evaluate 
because t he clinical improvement is unimpressive, t he di eases 
ar e self-limi t ing, or controlled stud ies using bilateral compar-
sion techniques have not been performed. Atopic eczem a, pi-
tyriasis rosea, parapsoriasis, and other diseases are occasionally 
improved by repeated exposures to sun or to artificial sources. 
In these dermatoses t he therapeut ic mechanism is not docu-
mented or understood. 
Paradoxically, certain photodel'matoses can be improved by 
cont roll ed exposures to ult raviolet radiation. In this case the 
side effects may include both normal and abnormal responses 
to the radiation, but continued therapy eventually increases 
tolerance to sunlight. Some investigators have used short 
CO UTses of systemic steroids to diminish the radiation-induced 
erupt ion during the early phases of treatment and successfully 
withdj'awn them as treatment continues [5]. T he mechanism of 
this type of treatment is a lso not known. P hototherapy and 
photochemotherapy of photodermatoses may induce melano-
genesis or injure cells involved in the pathogenesis of the 
photosensitivity. For instance, in polymorphous light eruption 
(PMLE) it is likely that both of t hese mechanisms aJ'e involved 
[6]. P hototherapy, heliotherapy, or oral psoralen photochem-
otherapy ar e known to be cytotox ic to lymphocytes [7,8]. Lym-
phocytes are found in increased number in the dermis ofPMLE 
lesions a nd these ceJJs may be necessary to support the disease 
process. Ultraviolet-induced delayed melanogenesis and t hick-
ening of t he epidermis would be expected to provide photopro-
tection . D epletion of mediators may also be involved but there 
is no evidence to date for this mechanism. Lymphocytotoxicity 
may also be operative in successful oral psoralen photochem-
otherapy of mycosis fungoides [9] or lichen planus [10]. 
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TABLE l. Photo/,herapy and Pho/,ochem otherapy 
Possible Mechanisms: 
Phototoxicity of abnormal 
ce lls 
Induced normal protective 
responses 
Killing organisms 
Alteration of metabolite 














" Hematoporphyrin derivative refers to photoradiation therapy using 
hematoporphyrin derivative. 
/, (±) No convincing evidence that disease process is altered. 
" (-) Double-blind ;;;tudies show no successful examples to date. 
SimilaT mechanisms may be involved in PUVA treatment of 
vitiligo [11). Lymphocytes are found in increased numbers 
during active progression of the disease and phototoxic effects 
on these cells would diminish the influence of the cells and 
possibly thereby playa permissive role in the host's attempts 
to repigment. PUV A induction of melanogenic response may 
also be operative but in a disorder chaTacterized by absence of 
recognizable epidermal melanocytes this response may be con-
fined to stimulation of migration and subsequent multiplication 
of hair bulb and perilesional melanocytes. This mechanism may 
be a minor component of the melanogenic response of normal 
skin, but may be the only component available to the vitiligo 
patient. It is known that repeated exposures of skin to ultravi-
olet radiation leads to increased numbers of functioning mela-
nocytes [12). 
Ultraviolet phototherapy and heliotherapy are widely rec-
ommended treatments for acne. Proposed mechanisms include 
claims that bactericidal effect reduces number of C. acnes, or 
that proliferogenic stimulus in the superficial portion of hair 
follicles leads to focal desquamation which acts to mechanically 
remove plugs or debris. There is no evidence for either of these 
mechanisms in vivo. It is possible that the increased blood flow 
that accompanies ultraviolet-induced inflammation accelerates 
regression of inflammatory lesions by enhanced clearance of 
media~ors of inflammation or by accelerated removal of toxic 
metabolites. [13). One possibility is that ultraviolet photother-
apy does not diminish acne but simply provides a mask of 
erythema and pigmentation which minimizes cosmetic liabili-
ties of the disease. No controlled studies have proven that 
phototherapy reduces the number of new lesions. One careful 
bilateral comparison study of PUV A treatment of acne showed 
no significant improvement [14). However, sunbathing and 
summertime vacations often are accompanied by improvement 
of acne. Infrared radiation may hasten healing of lesions by 
increasing blood flow and the often expressed psychological 
benefit many persons associate with sunbathing may be helpful 
via central nervous system or endocrinologic pathways. 
The mechanism of action of some forms of phototherapy 
appeaTS to be photochemical alteration of extracellular chemi-
cals present in skin and blood. Generalized pruritus, a common 
symptom of chronic renal failure, has been reported to be 
diminished by 6 to 8 exposures of erythemogenic doses of UVB 
[15). Expos\ue to markedly suberythemogenic doses of UVA 
(considered to be placebo therapy) was ineffective. In patients 
with uremic pruritus maintained on hemodialysis, photother-
apy of one side of the body results in generalized improvement 
without localization of the beneficial effect on the exposed side. 
This suggests that the therapeutic effects may result from 
photoinactivation of a pruritus-producing circulating substance 
present in uremia [16]. 
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Direct in situ intracutaneous extracellulaJ' photochemistry 
also seems the most likely mechanism in phototherapy of 
hyperbilirubinemia. While it is known that bilirubin can be 
photodegraded by photooxidative processes in vitro, this is 
probably not the only or most important therapeutic mecha-
nism in vivo. Photoisomerization of unconjugated bilirubin 
results in a more water soluble form which can apparently pass 
directly into the bile [17]. The fact that unconjugated bilirubin 
appears in the gastrointestinal tract in increased amount after 
phototherapy of jaundiced humans and hyperbilirubinemic an-
imals supports this mechanism [18]. 
PHOTOTHERAPY OF PSORIASIS 
Phototherapy of psoriasis is moderately successful and widely 
used and the principles and approach to this therapy are 
instructive to those interested in phototherapy of other dis-
eases. Although the older literature is difficult to interpret 
because dosimetric, radiometric, and clinical evaluation paTam-
eters aTe often insufficient, it appears that ultraviolet radiation 
alone is only. moderately effective. Most patients improve but 
few clear completely [19-21]. Topical adjunctive agents are 
most often used. Tar and ultraviolet radiation (Goeckerman 
treatment) has been a standard in-patient treatment for more 
than 50 yr and is very effective [22,23]. Other commonly used 
topical agents may enhance the effectiveness of ultraviolet 
radiation. Recent studies using erythemogenic ultraviolet radia-
tion and topical lubricants achieve cleaTance of over 90% of 
patients in an average of 23 treatments [21,24,25]. Phototoxic 
exposure doses are required and most successful protocols result 
in intermittent or continuous erythema of uninvolved skin. 
Repeated exposures aTe necessary-in general 15 to 30 separate 
phototoxic events are required. Because UVR-induced inflam-
mation of uninvolved skin limits exposw'e dose, UVR doses can 
be increased as tolerance (thicker stratum corneum, melaniza-
tion) increases. Experience to date suggests that these increases 
are neceSSaTy. Roughly the same number of phototoxic events 
are required whether treatments are given 7, 5, or 3 times per 
week. Reports on twice weekly treatments are varied but Some 
investigators claim good results [26]. 
The therapeutic mechanism is not known. In normal sbn 
cell injury by photons leads to a temporary decrease in DNA: 
RNA and pI'otein synthesis which is followed by a rebound 
marked and prolonged increase in macromolecular synthesis 
[27-30]. Many other cell effects also occur. If enough cells are 
injured and release mediators, an inflammatory reaction OCcurs. 
Delayed erythema is only one component of this response. The 
tissue as a whole repairs itself and increases its protection 
against further ultraviolet exposures. Melanogenesis and thick-
ened stratum corneum are components of this response. It is 
assumed that in psoriasis the response to photons is quantita-
tively or qualitatively different so that repeated cell injury, in 
doses tolerated by normal skin, is therapeutic. Differentiation 
and cell kinetics normalize. It is assumed that photons must 
reach the pl'Oliferative comprutment. DNA is thought to be an 
important therapeutic taTget because psoriasis is a hyperproli-
ferative disease, UVR temporru'ily decreases DNA synthesis in 
normal skin, and other agents known to be effective in psoriasis, 
including tar, affect DNA. Other potential mechanisms include 
preferential lethal effects on abnormal cells, inhibition of re-
cruitment of cells from Go phase, gene effects, effects on dermal 
blood vessels, inhibition or killing of leukocytes, or photoirn-
munologic effects. Improvement (thinning of plaques and nor-
malization of kinetics and differentiation) and remission may 
be by different mechanisms. 
For wavelengths longer than 295 nm the action spectrum for 
phototherapy of psoriasis seems to pru'allel the erythema action 
spectrum. At all of these wavelengths, including UV A [31,32], 
repeated exposures to doses near erythema-producing doses 
leads to clearing of psoriasis. Treatment with the longest ultra-
violet wavelengths is impractical and possibly unsafe because 
large exposure doses are required. The phototherapy action 
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spectrum peaks sharply at 295 to 305 nm [33,34]. Ultraviolet 
radiation of wavelengths shorter than 295 nm is far more 
erythemogenic than therapeutic [26,33], possibly because of 
decreased transmission through a thickened stratum corneum 
[34]. These observations may in part explain benefi t of "selec-
tive ultraviolet phototherapy" (S.U.P., 300-325 nm) , popular in 
Europe. S.U.P. utilizes exposw'e sources which omit the shorter 
wavelength ultraviolet usually present in most phototherapy 
sources. 
A spectral shift toward longer wavelengths may also partially 
explain why heliotherapy at the Dead Sea appears to be more 
effective than solar phototherapy at other locations [35,36]. 
The D ead Sea is 1200 ft below sea level and solar radiation 
must therefore travel through a longer column of a ir. The 
increased pathlength causes shorter wavelengths to be prefer-
entially scattered and absorbed. However, this effect is small 
and other mechanisms such as the allegedly higher aerosol 
content neal' the D ead Sea may account for some shift in the 
UV A j UVB ratio. It is also possible that soaking in the sea 
water r emoves natural ultraviolet absorbers such as uroca nic 
acid. Because the barrier function of a bnormal tissue may be 
decreased, more absorbing molecules could be removed from 
the psoriatic plaques than from normal skin. This would be 
expected to selectively increase transmission of UVR into pso-
riatic tissue. 
A variety of oils and solutions decrease spectral remittance 
(reflection and back scatter) of ultraviolet radiation and visible 
light from psoriatic plaques but not from normal skin . The 
optical changes ar e broad spectrum, without spectral "charac-
ter," rapid, of large magnitude, and directly correlate with the 
refractive index of topical agent. This indicates that the reduced 
backscatter is not caused by ultraviolet absorption by the 
topical agents but is r elated to increased transmission of pho-
tons into the tissue and also suggests that refractive index-
matching mechanism is involved [37,38]. 
Even though crude coal tar is a weak but defini te photosen-
sitizer with action spectrum in UV A, the spectral sensitivity of 
tar-treated skin and the spectral power distribution of sources 
used in "Goeckerman" therapy usually result in UVB-induced 
phototoxicity [38]. Special UV A sources can be used to show 
that tar photosensitization is therapeutic but this treatment is 
impractical because skin pain results, long exposUl"e times are 
required, and long-term risks are not known [39-41]. 
Topical steroids are often used in patients being treated with 
tar and ultraviolet radiation a nd early in the course of photo-
therapy treatment it appears as though psoriasis improves more 
quickly in steroid sites. Steroid-treated sites look less red pos-
sibly because blood vessels in psoriatic plaques may also be 
susceptible to the known vasoconstrictor effect of teroids. 
Steroid-treated plaques also seem to more quickly decrease in 
substance and scales during the first several treatments. How-
ever, there is no convincing evidence that, in patients ade-
quately treated with tru' and UVR, topical steroids reduce the 
time or number of treatments requi.red to clear the disease. In 
patients treated with UVR alone, the vehicle and occlusion 
used to deliver the steroids may enhance phototherapy via 
optical cha nges of the surface of the psoriatic tissue. If steroids 
do not decrease the amount of phototherapy needed, then their 
use in phototherapy may not be justified. Topical steroids are 
expensive and prolonged use may alter the nature of the pso-
riasis making it more aggressive, fragile, and difficult to manage. 
Atrophy of norma l skin may also occur a nd be additive to some 
of t he aspects of long-term actinic effects of phototherapy. 
More studies ru'e needed. 
Ultraviolet phototherapy has a lso been used in combination 
with other topical agents such as liquor carbonis detergens 
[42,43] a nd with dit hranol [44,45]. The relative effectiveness is 
variable and depends in part on the ultraviolet doses used. The 
combination of ultraviolet phototherapy with orally adminis-
tered retinoic acid deriva tives appears to offer the .short-term 
advantage of inducing remission with fewer phototherapy treat-
ments [46], but duration of remission and long-term risks re-
quire furt her study. 
Phototherapy of psoriasis can be made safer and more effec-
tive. Methods of selectively increasing UV transmission into 
psoriatic tissue include refractive index matching, alteration of 
the surface of psoriasis, mechanical removal of scale, and selec-
t ive elution of natural UV -absorbing substances from the ab-
normal tissue. Waveband selection may fUl"ther improve effec-
tiveness and r educe risks. Possibilities include the use of 
waveband interactions, monochromatic radiation, or souJ"ces 
wi t h spectral power distribut ion matching phototherapy action 
spectrum. The effectiveness of maintenance therapy is uncer-
tain. If the frequency of treatment required is great, then 
main tenance may become impractical and too costly in terms 
of actinic degeneration. Large mul t icenter t rials may be neces-
sary to qua ntify long-term risks and to answer questions about 
maintenance and remission times. There is presently a trend 
back toward increased use of UVB phototherapy. It would be 
disappointing if it was treated as an old friend slightly dressed 
up in dosimetry and more elegant topical medications. It should 
be approached as Ii new therapy in need of careful study. 
PHOTO CHEMOTHERAPY 
Photochemotherapy is the use of a chemical plus subsequent 
nonionizing electromagnetic radiation to achieve a therapeutic 
benefit. An exogenous chromophore 0 1' photosensitizer is added 
to attempt to influence the site a nd nature of t he photochem-
istry and subseq uent photobiologic effects. Usually in t he doses 
used the chemical alone 01' the radiation alone have no signifi-
cant biologic effect. The chemical may be given topically or 
pal'enterally but must reach viable cells which absorb subse-
quent radiation. There have been 3 major attempts to use this 
form of in vivo photochemistry for therapy in dermatology. 
The Goeckerman regimen was conceived to be and believed to 
be augmented phototherapy by topical photosensitization with 
crude coal tru', but as discussed above, this treatment as used 
today apperu's to be mainly UVB photothel·apy. "Dye-light" 
treatment of recurrent herpes simplex with neuu'al red or 
proflavin and subsequent UVA 01' visible ligh t has not proven 
to be an effective therapy [47]. Psoralen-UV A (PUV A) therapy 
was discovered thousands of years ago and remains the best 
example of successful photochemotherapy. A 4th example of 
photochemqtherapy is hematoporphyrin derivative-visible light 
therapy of human cancel' [48]. 
Psoralens are tricyclic fuj"o coumarins found in cer ta'in plants 
which a re capable of photosensitizing a wide vru'iety of cells. 
Some are capable of intercalcating into the DNA helix and 
subsequent absorpt ion of a photon leads to cyclobutane addi-
tion primarily to pyrimidines. T his add uct may absorb a second 
photon to form a cyclobutane bridge with a pyrimidine on t he 
opposite DNA strand and crosslinks occur. These DNA lesions 
may be repau'ed but may also lead to cell death, malfunction or 
mutation. In vivo studies have shown the major photochemistry 
to be within the UVA spectrum. While the DNA photoproducts 
are the most studied and discussed , other photochemical reac-
tions occur in cells with psoralen acting as photosensitizer. 
Purposeful in vivo psoralen- UV A photochemistry improves a 
vru'iety of skin diseases. Actual therapeutic mechanisms of 
PUV A treatment are lru'gely unknown. For psoriasis, the same 
hypotheses stated above for phototherapy may al 0 be invoked. 
For other diseases such as mycosis fungoides selective cytotox-
icity may be beneficial and in polymorphous light eruption 
melanogenesis may be a mong the therapeutic mechanisms. 
Because of the large variation in effi cacy, number of treatments 
required, and the maintenance r equirements, the risk/benefit 
considerations are diffe rent for each dermatoses treated with 
PUVA (see Table II). 
For PUV A and ul traviolet phototherapy where phototoxocity 
is the most likely central t herapeutic mechanism, the list of 
potential long-term side effects is the same. However, there are 
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TABLE II. Diseases Responding to PUVA" 
Number 
of Continued Treallnent T reat- Requirements Hesponse Ha te 
men lS to 
Clearing 
Psoriasis 10-40 Yes, variable 0 to 60/yr 90% 
Mycosis fungoides 20-60 Yes, usua lly frequent; 80+% Improve-
occasional re lnis.')ions ment 
Vitiligo 100- 400 Not usually, if towlly re- 70% Im proved 
pigmented 
E CZe ll'Ia 20-60 Yes, frequent 90% with aggres-
s ive therapy 
Lichen planus 10-20 Yes, variable 80+% 
Urticari a pib'lTlen- 15-30 Yes 80+% 
tosa 
Poly morphous light 10-20 Probably_ each spring 90+% 
eruption 
Actinic re licul oid 12('1) Yes I Case re port 
Alopecia areata 5-30 Unknown Over half 
Pa lmar/ plantar der- 20-60 Usua lly 90+% 
mUlitis 
" Diseases reported tQ respond to oral psoralen photochemotherapy. The Lable 
has been modified from Heference 57, in which the primary references to each 
entry ca n be loca ted . 
major differences between the two methods of using photons to 
injure or alter cells. 
The depth profile and average depth of in vivo phctochem-
istry is different for PUV A and UVB. The precise therapeutic 
action spectrum for PUV A is not known but it is assumed that 
a major portion of the therapeutic benefit occurs with radiation 
within the UV A range. UV A penetrates into skin deeper than 
does UVB. Shorter wavelength ultraviolet radiation is prefer-
entially absorbed by specific biomolecules within the epidermis 
(49). Scatter is inversely and exponentially related to wave-
length so that shorter wavelength ultraviolet radiation has 
longer pathiengths which fw-ther increases chance for absorp-
tion within the epidermis. In a fair Caucasian as much as 50% 
of the UV A dose incident on the surface of the skin is trans-
mitted into the dermis while much less than 10% of the sW'face 
UVB dose reaches that level [50]. In psoriasis, a thick stratum 
co rneum and scale further increases the optical barrier and the 
proliferative compartment is deep within the tissue. Appar-
ently, for successful therapy, photons must reach the prolifer-
ative compartment, blood vessels or dermal cells. 
Psoralen-DNA photoproducts most likely have different ef-
fects on cells and are repaired differently than the UVB-induced 
DNA photoproducts. The most stable, easily isolated, and most 
studied photoproduct of DNA radiation by UVB is the t hymine 
dimeI'. Other photoproducts also occur, but crosslinks from 
UVB are very raj·e. The non-DNA mechanisms of cell photo-
toxicity also differ but less is known about in vivo ultraviolet-
induced protein, RNA, or membrane lesions. For example, 
while both PUV A [51] and UVB [52] are known to decrease 
viability and function of human peripheral blood lymphocytes, 
the relative mechanisms of phototoxicity are at least quantita-
tively different. With UVB, trypan blue exclusion (most likely 
a membrane function) is diminished at lower doses than re-
quired to diminish PHA-induced blastogenic response. The 
reverse is true with PUVA [52]. 
The inflammatory response induced by PUV A is different 
from that induced by UVB. Prostaglandins are associated with 
the initial portion of the UVB-induced delayed erythema but 
. based on indirect evidence to date, this does not seem to be the 
cas~ with PUV A [53]. Generalized symptomatic UVB-induced 
erythema is accompanied by a polymorphonuclear leukocytosis 
which does not occur with PUV A [8]. Delayed erythema after 
sufficient UVB exposure begins after a latent period of a few 
hours and reaches its peak at 12 to 24 hr. After PUV A, erythema 
usually does not begin for 24 hI' and maximizes at 48-96 hr. 
The erythema dose-response curve is steeper with PUVA than 
with UVB. H istologic studies comparing equally erythemogenic 
exposw-e doses of UVB + PUV A show that in normal skin 
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PUV A has more effect on blood vessels and that epidermal 
alterations last much longer [54]. 
The importance of the differences between in vivo photo-
biologic effects of PUV A and UVB is not known. Both agents 
are known photocarcinogens and both are expected to add to 
cumulative actinic insult of skin. Both are lymphocytotoxic 
with potential long-term effects. The greater depth and effective 
tissue volume of in vivo photochemistry may explain Why 
several studies have found PUV A to be more rapidly effective 
than UVB in some patients a nd why topical lubricants enhance 
the therapeutic effect of PUV A less than UVB. On the other 
hand, because of the deeper average depth of in vivo photo-
chemistry PUV A may be more likely to cause irreversible 
actinic changes because of its greater percentage of dermal 
effects. The viability and function of lymphocytes or other 
intravascular or extravascular cells in the dermis may be more 
easily affected by PUV A and this may increase therapeutic or 
non therapeutic effe'cts. PUV A may be more lethal to certain 
cells or be a more effective mutagen because the repair of the 
monofunctional or bifunctional photoadducts may be by error-
prone pathways other than the major DNA pathways evolved 
to repair the more usual DNA photoproducts caused by sun 
exposw-e without psoralens. Monofunctional psoralen-DNA ad-
ducts may lead to frame shift type of mutations. On the nther 
hand, crosslinking may be less absolutely mutagenic because it 
is a more lethal event. Mutations per sw-viving cell may be the 
appropriate parameter to consider regarding photocarcinoge_ 
nesis. More studies are needed. 
Efficacy and side effects are likely affected by all of these 
differences. The best example of a qualitatively different risk is 
the primary eye hazard . Unintentional overexposw-e to UVB 
causes an acutely symptomatic photokeratitis which is usually 
reversible [55]. The major risk to the unprotected eye of the 
PUV A patient is the development of cataract [56], a permanent 
decrease in visual acui ty whose onset may be delayed for years. 
The differences which make PUV A a more potent phototoxic 
insult may make it more therapeutic but may also increase 
long-term toxicity. Considering the nature of psoriasis, it i 
likely that the 3 properties are closely, possibly inseparably, 
tied together. But it is certainly possible that new psoralens or 
new approaches may allow separation of these effects. Much 
more basic and clinical information is needed. 
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